Johnson & Johnson Enters Agreement to Acquire Atraverse Medical

NEW BRUNSWICK, N.J. – April 24, 2026 – Johnson & Johnson (NYSE: JNJ) has entered into a definitive agreement to acquire Atraverse Medical, Inc., a privately-held medical device company pioneering next-generation left-heart access and radiofrequency (RF) technology.

Achieving safe and precise access to the left atrium remains one of the most critical steps in atrial fibrillation ablation. Atraverse Medical’s HOTWIRE™ Transseptal Access System, already used in nearly 3,000 clinical procedures, is an FDA-cleared RF guidewire and generator system that is designed for greater confidence and control when accessing the left atrium. The system offers multiple innovative features—including impedance-sensing automatic energy shutoff, compatibility with multiple sheaths, and clear tip visibility under intracardiac echocardiography—that support smooth and efficient access to the left atrium.

The planned acquisition of Atraverse Medical would strengthen Johnson & Johnson’s portfolio of cardiac ablation solutions, bringing electrophysiologists innovative tools to treat patients with atrial fibrillation and other cardiac arrhythmias. The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions. Financial terms of the transaction are not being disclosed.

Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the potential acquisition of Atraverse Medical. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: the satisfaction of closing conditions for the acquisition; the possibility that the transaction will not be completed in the expected timeframe or at all; the potential that the expected benefits and opportunities of the acquisition, if completed, may not be realized or may take longer to realize than expected; challenges inherent inproduct research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; economic conditions, including currency exchange and interest rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; legal proceedings; changes to applicable laws and regulations, including tax laws and global health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and trends toward health care cost containment. In addition, if and when the transaction is consummated, there will be risks and uncertainties related to the ability of the Johnson & Johnson family of companies to successfully integrate the products and employees of Atraverse Medical, as well as the ability to ensure continued performance or market growth of Atraverse Medical’s products. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.